Form 4: Xenon Pharma CLO Sells Shares for Tax Obligations
Insider Transaction Report
Xenon Pharmaceuticals' Chief Legal Officer, Andrea DiFabio, sold shares to cover tax obligations following the vesting of restricted stock units.
Summary
- Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals Inc. (XENE), reported transactions involving company common shares.
- On March 12, 2026, DiFabio acquired 3,750 common shares due to the vesting of a Restricted Share Unit (RSU) award.
- The RSU award was granted on March 12, 2025, and vests 25% annually over four years, with the first vesting occurring on March 12, 2026.
- On March 13, 2026, DiFabio disposed of 1,342 common shares at a price of $55.225 per share.
- This sale was executed under a Rule 10b5-1 trading arrangement, adopted on December 3, 2025, specifically to satisfy tax withholding obligations related to the RSU vesting.
- Following these transactions, DiFabio beneficially owns 7,301 common shares directly and 11,250 derivative securities (Restricted Share Units).
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a slightly positive event for the insider, representing earned compensation, and a neutral event for the company's stock, as the sale was a routine, tax-driven transaction under a pre-established plan.
Positives
- The vesting of 3,750 Restricted Share Units represents earned compensation for the Chief Legal Officer, indicating continued alignment of executive incentives with company performance.
Future Outlook
The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider transactions.
Management Comments
- The sales reported were effected pursuant to a Rule 10b5-1 trading arrangement, in the form of a durable sell-to-cover instruction, adopted by the reporting person on December 3, 2025, solely to satisfy tax withholding obligations related to the vesting of RSUs granted on March 12, 2025.
Industry Context
StockSavvy.ai notes that insider transactions, particularly those involving sell-to-cover for tax purposes under a pre-arranged 10b5-1 plan, are common and generally do not signal a change in management's outlook on the company's prospects. Such transactions are routine for executives receiving equity compensation.
Stakeholder Impact
- Shareholders: The sale of shares by a Chief Legal Officer for tax purposes is a routine event and typically has minimal impact on shareholder sentiment or the company's operational outlook.
- Employees: The vesting of RSUs is a standard form of equity compensation, aligning executive interests with long-term company performance.
Next Steps
- Future vesting of the remaining Restricted Share Units on the first four anniversaries of the March 12, 2025 grant date.
Key Dates
| Date | Description |
|---|---|
| 2025-03-12 | Grant date of the Restricted Share Unit (RSU) award to Andrea DiFabio. |
| 2025-12-03 | Date Andrea DiFabio adopted the Rule 10b5-1 trading arrangement. |
| 2026-03-12 | Date of RSU vesting, resulting in the acquisition of 3,750 common shares. |
| 2026-03-13 | Date of sale of 1,342 common shares to satisfy tax withholding obligations. |
Keywords
Xenon Pharmaceuticals, XENE, Insider Trading, Form 4, Restricted Share Units, RSU, Sell-to-Cover, Tax Obligations, Andrea DiFabio, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.